No abstract

Background: TALE-based technologies are poised to revolutionize the field of biotechnology; however, their sensitivity to cytosine methylation may drastically restrict their ranges of applications. Results: TALE repeat N* proficiently accommodates 5-methylated cytosine. Conclusion: Sensitivity of TALE to cytosine methylation can be overcome by using TALE repeat N*. Significance: Utilization of TALE repeat N* enables broadening the scope of TALE-based technologies.Within the past 2 years, transcription activator-like effector (TALE) DNA binding domains have emerged as the new generation of engineerable platform for production of custom DNA binding domains. However, their recently described sensitivity to cytosine methylation represents a major bottleneck for genome engineering applications. Using a combination of biochemical, structural, and cellular approaches, we were able to identify the molecular basis of such sensitivity and propose a simple, drug-free, and universal method to overcome it.Transcription activator-like effectors (TALEs), 4 a group of bacterial plant pathogen proteins, have recently emerged as new engineerable scaffolds for production of tailored DNA binding domains with chosen specificities (1). Interest in these systems comes from the apparent simple cipher governing DNA recognition by their DNA binding domain (2, 3). The TALE DNA binding domain is composed of multiple TALE repeats that individually recognize one DNA base pair through specific amino acid di-residues (repeat variable di-residues or RVDs). The remarkably high specificity of TALE repeats and the apparent absence of context-dependent effects among repeats in an array allow modular assembly of TALE DNA binding domains able to recognize almost any DNA sequence of interest. Within the past 2 years, engineered TALE DNA binding domains have been fused to transcription activator (dTALEs) (4), repressor (5), or nuclease domains (TALENs) (6) and used to specifically regulate or modify genes of interest (1). Although successfully used in different cellular contexts, engineered TALE DNA binding domains have recently been reported to be affected by the presence of 5-methylated cytosine (5mC) in their endogenous cognate target (7). Often considered as the fifth base, 5mC is found in about 70% of CpG dinucleotides in mammalian and plant somatic/pluripotent cells (8, 9) and has also been reported in 5-cytosine-phosphoadenine, 5-cytosine-phosphothymine, and 5-cytosine-phosphocytosine dinucleotides (10). Moreover, 5mC has been identified in CpG islands embedded in many promoters (11) and, to a higher extent, in proximal exons of several genes (12). These two critical regulatory regions are generally chosen by investigators to knock out genes of therapeutic and biotechnological interest or to modulate their expression using TALE-based technologies. The ubiquity of 5mC in different cell types and genomic kingdoms, its particular localization, and its negative impact on dTALE activity reported in Ref. 7 make this epigenetic modification a major dra...

A key to the success of chimeric antigen receptor (CAR) T-cell based therapies greatly rely on the capacity to identify and target antigens with expression restrained to tumor cells. Here we present a strategy to generate CAR T-cells that are only effective locally (tumor tissue), potentially also increasing the choice of targetable antigens. By fusing an oxygen sensitive subdomain of HIF1α to a CAR scaffold, we generated CAR T-cells that are responsive to a hypoxic environment, a hallmark of certain tumors. Along with the development of oxygen-sensitive CAR T-cells, this work also provides a basic framework to use a multi-chain CAR as a platform to create the next generation of smarter self-decision making CAR T-cells.

A key issue when designing and using DNA-targeting nucleases is specificity. Ideally, an optimal DNA-targeting tool has only one recognition site within a genomic sequence. In practice, however, almost all designer nucleases available today can accommodate one to several mutations within their target site. The ability to predict the specificity of targeting is thus highly desirable. Here, we describe the first comprehensive experimental study focused on the specificity of the four commonly used repeat variable diresidues (RVDs; NI:A, HD:C, NN:G and NG:T) incorporated in transcription activator-like effector nucleases (TALEN). The analysis of >15 500 unique TALEN/DNA cleavage profiles allowed us to monitor the specificity gradient of the RVDs along a TALEN/DNA binding array and to present a specificity scoring matrix for RVD/nucleotide association. Furthermore, we report that TALEN can only accommodate a relatively small number of position-dependent mismatches while maintaining a detectable activity at endogenous loci in vivo, demonstrating the high specificity of these molecular tools. We thus envision that the results we provide will allow for more deliberate choices of DNA binding arrays and/or DNA targets, extending our engineering capabilities.